Clinical Trials Logo

Clinical Trial Summary

BCG vaccination, the most widely used vaccination in the world, is used to reduce risk of tuberculosis infection; it is used for other mycobacterial infections as well, benefiting leprosy and Buruli ulcer. BCG has "heterologous" effects that aids in an array of non-mycobacterial and viral infections as well as bladder cancer. It is the heterologous effect, sometimes called the "off-target" effect that may offer benefit in Alzheimer's disease. Population studies and studies of adults receiving BCG show a lessened risk of Alzheimer's disease. The study will see if BCG vaccination will alter a plasma test for amyloid, a biomarker for cerebral amyloid.


Clinical Trial Description

Alzheimer's disease (AD) is commonly regarded as Alzheimer's dementia. It is now understood that changes in the brain that result in late-onset AD dementia start years or even decades prior to clinical dementia. Biomarkers aid in diagnosing AD however, currently approved biomarkers have drawbacks as they are invasive and expensive. The two most commonly used biomarkers are amyloid PET scan and spinal tap for amyloid and tau. A new plasma amyloid test has received "Breakthrough Device Designation" from the US-FDA. As an investigational tool, this blood test for amyloid peptides 42/40 levels accurately predicts brain amyloidosis in cognitively normal individuals. In the past 100 years, four billion doses of BCG vaccination have been given for tuberculosis prevention. A favorable effect with BCG for non-tuberculous mycobacteria is also recognized in cervical lymphadeniits, leprosy and Buruli's ulcer. Recently, BCG has found favorable use in autoimmune diseases type 1 diabetes (T1D) and multiple sclerosis (MS); moreover, a protective role by BCG for Alzheimer's disease has been described. Adult exposure to BCG lessened the risk of AD by four-fold. This is an interventional pilot study to test 50 non-demented adults measuring their plasma amyloid 42/40 level prior to BCG prime/boost followed with the same plasma amyloid testing 9 months after vaccination. Sub-clinical CMV infection is felt to drive immune senescence and increase the risk of AD; we will test for CMV antibodies and we will measure lymphocyte phenotype prior to BCG and at study end to look for an immune-modulating effect on this indicator of immunosenescence. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04449926
Study type Interventional
Source Mindful Diagnostics and Therapeutics, LLC
Contact
Status Completed
Phase Phase 2
Start date November 9, 2020
Completion date December 5, 2021

See also
  Status Clinical Trial Phase
Completed NCT05407272 - Explore the Sharing Model Intervene to Improve the Knowledge, Attitudes, Service Intentions and Service Start-up Effects of the Eight Major Non-cancer Disease End-stage Caregivers on Well-being and Palliative Care N/A
Completed NCT02958930 - Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease N/A
Recruiting NCT06203106 - NYSCF Scientific Discovery Biobank
Active, not recruiting NCT03661034 - Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study) N/A
Not yet recruiting NCT05183516 - Tdap and Biomarkers of Alzheimer's Disease Phase 1/Phase 2
Recruiting NCT04263194 - Network-based rTMS in Alzheimer's Disease N/A
Recruiting NCT04100889 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
Completed NCT02187276 - The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia N/A
Recruiting NCT04680013 - Genetic Studies in Familial Dementia
Recruiting NCT04270474 - Reducing Risk of Dementia Through Deprescribing N/A
Not yet recruiting NCT06448403 - Multimodal Assesment of Alzheimer Patients
Enrolling by invitation NCT06078891 - Does BCG Vaccination Reduce Biomarkers of Alzheimer's Disease? Early Phase 1
Recruiting NCT05138848 - Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease N/A
Withdrawn NCT03149380 - Effectiveness of Alzheimer's Universe (Www.AlzU.Org) on Knowledge and Behavior N/A
Recruiting NCT03653156 - China Cognition and Aging Study
Completed NCT03300726 - Synaptic Injury and Functional Connectivity in Alzheimer's Disease
Recruiting NCT01773915 - New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study N/A
Recruiting NCT05655195 - Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy N/A
Recruiting NCT05637801 - A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011) N/A
Recruiting NCT03153371 - Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks